Cervical Cancer Vaccine Gets Priority Review From FDA
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on February 10, 2006

Gardasil is designed to protect against four types of human papillomavirus (HPV):
- types 16 and 18, which account for an estimated 70 percent of cervical cancer cases and
- HPV types 6 and 11, which account for an estimated 90 percent of genital wart cases.
Merck has also submitted applications for Gardasil to additional regulatory agencies in the European Union, Australia, Mexico, Brazil, Argentina
, Taiwan and Singapore.Gardasil is cited by Forbes to be one of the next drugs to watch, estimating its potential at $500 million to $1 billion in annual sales.
Permalink: Cervical Cancer Vaccine Gets Priority Review From FDA
Tags:
cervical cancer biotech vaccine review cervical+cancer cancer+vaccine priority+review
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/15183





